Biosimilars in Oncology: Update Bulletin
[Lowest Price Guaranteed: $995]
Published by FirstWord Pharma: 01 Feb 2016 | 304 | In Stock
Related Topics: Services
new KOL insights on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz’s PROTECT 1 and PROTECT 2 studies which both compared the safety and efficacy of LA-EP2006 (a proposed pegfilgrastim biosimilar) to Amgen’s Neulasta in patients with breast cancer; the regulatory filing of Celltrion’s proposed rituximab biosimilar, CT-P10, to the European Medicines Agency (EMA), and the concerns KOLs have in relation to the potential for indication extrapolation from the rheumatology to oncology settings; the potential impact of The Centers for Medicare & Medicaid Services’s (CMS) final rule on how it plans to reimburse for biosimilars covered under Medicare Part B in the US.
Key Questions Answered in this Update Bulletin:
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Table of Contents
for Biosimilars in Oncology: Update Bulletin [Feb 2016]
|Title||Date Published||Price from||More Details|
|amp biosimilars AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile|
Summaryamp biosimilars AG (amp biosimilars) is a biopharmaceutical company that develops biosimilars...
|24 Aug 2016 by Global Data||USD $250||More Info|
|Biosimilars in Oncology: KOL Insight|
IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologi...
|01 Jan 2016 by FirstWord Pharma||USD $7,900||More Info|
|Biosimilars: European Payer Perspectives (2016)|
IntroductionWhat’s driving the uptake of biosimilars in Europe and what still needs to be done?The E...
|01 Jan 2016 by FirstWord Pharma||USD $2,195||More Info|
|Biosimilars: Regulatory Outlook|
IntroductionBiosimilars offer a chance to improve access to, and reduce spending on, life-saving bio...
|01 Nov 2015 by FirstWord Pharma||USD $2,195||More Info|
|The Future of Biosimilars 2015|
IntroductionThe Future of Biosimilars 2015 offers expert insight and opinion on the key issues facin...
|01 Jun 2015 by FirstWord Pharma||USD $2,195||More Info|
|Biosimilars: US Payer Perspectives|
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
|01 Apr 2015 by FirstWord Pharma||USD $2,195||More Info|
|Biosimilars: European Payer Perspectives|
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
|06 Jan 2015 by FirstWord Pharma||USD $2,195||More Info|
|The Future of Biosimilars: mapping critical uncertainties and the impact of future events|
IntroductionThe Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Event...
|05 May 2014 by FirstWord Pharma||USD $1,950||More Info|
|Commercialisation of Biosimilars: strategies for market penetration|
IntroductionTimes, they are a-changin’—at least for the American biological product market. With fiv...
|01 Nov 2013 by FirstWord Pharma||USD $695||More Info|
|Biosimilars in Emerging Markets|
IntroductionWhat are the implications for regulators, biosimilar companies and branded manufacturers...
|01 Mar 2013 by FirstWord Pharma||USD $665||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.